Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.It was approved for medical use in the United States in September 2021. Medical uses
Atogepant is indicated for the preventive treatment of episodic migraine in adults. Research
A study found that atogepant reduced the number of migraine days over twelve weeks. References
External links
"Atogepant". Drug Information Portal. U.S. National Library of Medicine.
This denial of behaviour can be seen as a way to overcome anxiety and helplessness brought on by the stressful event that often precedes the syndrome.These aetiological debates focus on the main symptom of Ganser syndrome and its importance in its diagnosis. Approximate answers are prominent in the Ganser syndrome literature, causing concern in those who believe that this is a relatively simple symptom to feign.Ganser syndrome was regarded as an Adjustment Reaction of Adult Life in the DSM-II and later was moved under the category of Factitious Disorder with Psychological Symptoms in the DSM-III. Ganser syndrome can also be found under the Dissociative Disorder Not Otherwise Specified (DDNOS) section of the DSM-IV-TR, however it is not listed in the DSM-5, which got rid of the DDNOS section and replaced it with Other Specified Dissociative Disorder (OSDD) and Unspecified Dissociative Disorder (USDD). Despite this, the International Classification of Diseases has Ganser syndrome listed under dissociative disorders. See also
Paraphasia

References
Further reading
Schutzman, Mady (2003). "Being Approximate: The Ganser Syndrome and Beyond" (PDF). Journal of Medical Humanities. 24 (1/2): 147–158. doi:10.1023/A:1021318118143. S2CID 141323730. Retrieved 14 December 2010. == External links ==